A Dose-response Study With Strontium Malonate in Postmenopausal Women

Inclusion Criteria: * Postmenopausal women (at least 12 months since last menstruation). * BMD (L2-4) T-score between -1 and -3 (at least 20% of the enrolled patients must have a BMD (L2-4) T-score below -2,5). * 50 years of age. * BMI\<30 kg/m2. * Total S-Ca level within normal range. * Ability to read and understand the information given. * The patient has signed an informed consent form according to ICH E6 and local requirements before any study specific procedure is carried out. * Ability to comply with study procedures. Exclusion Criteria: * History of prior fragility fracture (any fracture in wrist, hip or spine appearing after 40 years of age). * History of alcohol or drug abuse. * Metabolic bone disease (e.g. pagets disease, bone cancer). * History of VTE/DVT. * History of kidney transplant. * Bilateral oophorectomy. * Relevant and treated reduced kidney or liver function. * Any malignancy within the last 5 years (except basal cell carcinoma) * Any chronic condition likely to affect absorption (e.g. Crohns disease, gluten enteropathy). * Known genetic pre-disposition to VTE/DVT * Known hypersensitivity to any of the active substances or excipients. * 25-OH-vitamin D level below 25 nmol/L * Any previous treatment with bisphosphonates, Strontium or fluoride. * Treatment during the last 3 months affecting calcium balance or bone metabolism (e.g. thiazides, corticosteroids, calcitonin, HRT, SERMs, PTH, phosphorus). * Treatment during the last week with tetracycline, ciprofloxacin or loop diuretics. * PTH out of normal range * Use of any drug known to influence the coagulation process (aspirin and other NSAID allowed) * Prothrombin time out of normal range (sec or INR) * Inclusion in another clinical study within 30 days before randomization or during this study